Protalix Biother Stock Price, News & Analysis

Protalix BioTherapeutics, Inc. (NYSE American: PLX) announced that President and CEO Dror Bashan will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 11:00 a.m. EDT in New York City. The conference runs from September 12-14, 2022, and includes options for virtual participation. A live corporate overview will be webcast, replacing a prior pre-recorded presentation. Management will also engage in one-on-one investor meetings during the event.

Protalix specializes in recombinant therapeutic proteins through its ProCellEx® expression system.

Protalix BioTherapeutics (NYSE American: PLX) announced its participation at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, at the Lotte New York Palace Hotel. CEO Dror Bashan will present a corporate overview, and a live webcast will start at 7:00 AM ET on September 12. Protalix specializes in developing recombinant therapeutic proteins using its proprietary ProCellEx® system. The company has FDA approval for its first product, taliglucerase alfa, and is advancing several therapeutic candidates for various diseases.

Protalix BioTherapeutics, Inc. (NYSE American: PLX) announced its Q2 2022 financial results and business updates on August 15, 2022. The firm reported revenues of $3.4 million from goods, a 6% increase year-over-year, and $5.4 million from licenses and R&D services, a 69% increase. The cost of goods sold decreased by 13% to $4.1 million. Research expenses slightly fell by 1% to $7.6 million, while SG&A expenses dropped by 19% to $2.6 million. The net loss narrowed to approximately $5.3 million, down from $11.2 million in Q2 2021. Protalix confirmed positive results from the phase III BALANCE trial for PRX-102.

Protalix BioTherapeutics (NYSE American: PLX) will announce its second-quarter 2022 financial results and provide a business update on August 15, 2022. A conference call with investors is scheduled for the same day at 8:30 a.m. EDT, where management will discuss financial results and recent corporate updates. Protalix is known for its ProCellEx protein expression system and has FDA-approved products, including taliglucerase alfa. The company has a strong pipeline targeting various medical conditions.

Protalix BioTherapeutics (NYSE American: PLX) has appointed Shmuel 'Muli' Ben Zvi, Ph.D., to its Board of Directors. Dr. Ben Zvi, who brings extensive financial and management expertise, will also serve on the Audit and Compensation Committees. His prior experience includes senior roles at Teva Pharmaceuticals and positions on various boards including Bank Leumi. Protalix is known for its innovative plant cell-based expression system and has FDA-approved products, ensuring its commitment to developing recombinant therapeutic proteins.

Protalix BioTherapeutics (NYSE:PLX) announced five poster presentations to be featured at the 2022 Program: 7th Update on Fabry Disease, highlighting crucial clinical trial results. Scheduled from May 29-31, 2022, in Würzburg, Germany, presentations include data on the safety and efficacy of Pegunigalsidase Alfa for Fabry disease. Notable studies include 24-month results from the Phase III BALANCE study and long-term data from various trials. The presentations will be available on Protalix's website, showcasing its commitment to advancing treatment options in this therapeutic area.

Protalix BioTherapeutics (PLX) reported Q1 2022 financial results, showing a 100% revenue increase to $9.0 million compared to Q1 2021. The company advanced its Fabry disease treatment, PRX-102, completing three phase III trials and preparing for a BLA resubmission to the FDA. Key studies, BRIGHT and BALANCE, demonstrated significant efficacy and safety. R&D expenses rose by 24% to $8.8 million, while net loss improved to $2.3 million. The company holds $32.9 million in cash as of March 31, 2022. A conference call is scheduled for today at 8:30 a.m. EDT.

Protalix BioTherapeutics (NYSE: PLX) will release its first-quarter 2022 financial results on May 16, 2022, and host a conference call at 8:30 a.m. EDT. The call will address financials and provide updates on corporate and clinical developments. The company specializes in recombinant therapeutic proteins using its ProCellEx plant cell-based expression system, with FDA-approved products like taliglucerase alfa. Protalix is also developing several candidates targeting various diseases, including Fabry disease and respiratory conditions.

Protalix BioTherapeutics (PLX) and Chiesi Global Rare Diseases announced positive topline results from the BALANCE pivotal Phase III trial for PRX–102, a novel enzyme replacement therapy for Fabry disease. The trial, involving 78 adult patients, demonstrated non-inferiority of PRX–102 compared to agalsidase beta in slowing kidney function decline, a key outcome measure. The median eGFR slope in the PRX–102 group was -2.514 mL/min/1.73 m²/year, while the agalsidase beta group had -2.155 mL/min/1.73 m²/year. The favorable safety profile and positive results strengthen the case for regulatory submission for PRX–102's approval.